Related Experiment Video
Updated: Feb 21, 2026
06:02
A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model
Published on: November 6, 2020
18.0K
Does Dexamethasone Helps in Meningococcal Sepsis?
Ilir Tolaj1, Hamdi Ramadani1, Murat Mehmeti1
1Department of Infectious Diseases, University Clinical Centre in Pristina, Kosovo.
Medical Archives (Sarajevo, Bosnia and Herzegovina)
|October 5, 2017
Summary
Dexamethasone (DXM) shows benefits in treating invasive meningococcal disease (IMD) by shortening hospital stays and aiding white blood cell normalization. This study suggests DXM is a safe adjunctive treatment for IMD, even with limited benefits.
Area of Science:
- Infectious Diseases
- Clinical Pharmacology
- Critical Care Medicine
Background:
- Prompt recognition and aggressive early treatment are crucial for managing invasive meningococcal disease (IMD).
- The role of anti-inflammatory adjunctive treatments, such as dexamethasone (DXM), in IMD remains debated.
- Assessing the efficacy of adjunctive therapies in IMD is challenging due to disease complexity.
Purpose of the Study:
- To evaluate the impact of dexamethasone (DXM) as adjunctive therapy in various clinical presentations of IMD.
- To determine if DXM should be considered a routine treatment for invasive meningococcal disease.
- To assess the safety and efficacy of DXM in patients with meningococcal septicaemia and/or meningitis.
Main Methods:
- A non-interventional clinical study (NIS) included 39 patients with meningococcal septicaemia with or without meningitis.
- Patients receiving dexamethasone (DXM) were compared to those who did not receive DXM.
- Statistical analysis was performed using SPSS to compare outcomes.
Main Results:
- The study included 39 patients, with 76.9% presenting with both sepsis and meningitis.
- Dexamethasone (DXM) was administered to 61.5% of patients, showing significant statistical differences in length of hospitalization and WBC normalization.
- The overall mortality rate was 10.3%, with complications including pneumonia (15.4%) and arthritis (7.7%).
Conclusions:
- Dexamethasone (DXM) demonstrated proven benefits and no harmful effects as an adjunctive therapy in invasive meningococcal disease (IMD).
- Even limited benefits observed with DXM justify its recommendation as an adjunctive treatment for IMD.
- The findings support the use of DXM in managing this dangerous infection.
